Central to this innovative research is the Chromatin, Metabolism and Cell Fate laboratory, led by Dr. Marcus Buschbeck, whose work delves deeply into the molecular choreography that governs how genetic information is stored and accessed within cells. Chromatin, the densely packed complex of DNA and proteins, acts as the transcriptional gatekeeper, and histones—its fundamental protein components—play a pivotal role in maintaining genome integrity and regulating gene function. Mutations and dysregulation of histone proteins have been increasingly recognized as drivers of oncogenic transformation, especially in hematological malignancies, positioning them as tantalizing targets for therapeutic intervention.

Historically, however, histones have been regarded as “undruggable” entities. Their ubiquitous presence and essential roles in normal cell survival imposed a near-impossible hurdle for targeted therapies, as inhibiting these proteins could inflict severe toxicity. This longstanding assumption has hindered efforts to exploit chromatin dysregulation therapeutically, leaving a critical gap in the arsenal against blood cancers. Dr. Buschbeck’s team has taken a transformative approach by concentrating on a unique subset of histones known as macroH2A variants, which differ from canonical histones through their specialized structural domains and regulatory functions.

Among the macroH2A family, three variants—macroH2A1.1, macroH2A1.2, and macroH2A2—have drawn particular attention. Earlier studies hinted at a strong association between macroH2A dysregulation and the pathogenesis of Acute Myeloid Leukaemia. This nexus galvanized the research efforts to rigorously test the therapeutic potential of targeting these histone variants. The breakthrough came through a series of meticulous in vivo experiments, wherein each macroH2A variant was selectively ablated in murine models to assess the physiological ramifications and ascertain safety profiles.

The findings, published in a high-impact scientific journal, provided remarkable insights that defied expectations. Contrary to concerns about significant toxicity, the loss of macroH2A variants did not precipitate catastrophic adverse effects in normal mice. While most physiological parameters remained intact, the removal of macroH2A1.1 induced a subtle but notable kidney abnormality. This renal phenotype correlated with a metabolic shift—from lipid to glucose utilization—that, although intriguing, presented a manageable condition. Intriguingly, researchers demonstrated that dietary modulation could restore metabolic balance and reverse kidney lesions, thereby underscoring the feasibility of therapeutic targeting.

This revelation fundamentally redefines the therapeutic landscape, suggesting that macroH2A histones hold promise as safe and effective drug targets in blood cancers. By unmasking the nuanced biological roles of these variants, the study offers a new vantage point that reconciles chromatin biology with systemic metabolism—a nexus that could be exploited to achieve selective anticancer effects while sparing normal tissues. Consequently, this work has catalyzed a vibrant new line of investigation within the Josep Carreras Institute and among its global collaborators, with multiple research groups now exploring small molecules and other modalities aimed at modulating macroH2A function.

Beyond the biochemical and cellular intricacies, the team leveraged state-of-the-art platforms including the German Mouse Clinic and Helmholtz Center Munich’s expertise, utilizing comprehensive phenotyping pipelines that evaluate hundreds of physiological parameters. This extensive phenotyping lends robustness to the conclusions and paves the way for translational studies that could expedite clinical development. The interdisciplinarity embodied in this collaboration epitomizes the modern research paradigm, where genomics, metabolism, and physiology converge to unlock therapeutic breakthroughs.

In addressing the unmet needs in haematological oncology, this research integrates seamlessly with the Josep Carreras Institute’s strategic mission, which is dedicated not only to expanding fundamental knowledge but to translating discoveries into clinical advances. Through innovations such as the Computational Diagnostics Centre—which employs artificial intelligence fused with biological data—the Institute is redefining precision medicine for blood cancers, aiming to deliver targeted and personalized therapies that improve survival and quality of life for patients worldwide.

This promising avenue reflects a paradigm shift: histone variants, once sidelined due to presumed toxicity, are now emerging as druggable chromatin regulators with the potential to disrupt oncogenic pathways uniquely operative in leukaemia cells. The catalytic impact of such research resonates beyond leukaemia, hinting at relevance to a spectrum of haematologic malignancies and perhaps solid tumors, where epigenetic dysregulation is equally implicated.

Funding for this transformative study has been supported by prominent international scientific bodies, including the European Commission, the German Research Foundation, and a consortium of philanthropic foundations. Such cooperative investment underscores the global priority accorded to decoding cancer biology and enabling innovative treatment paradigms. Publishing in a prestigious platform ensures wide dissemination, inspiring parallel investigations and accelerating the innovation cycle from bench to bedside.

As the pursuit to conquer blood cancers advances, the identification of macroH2A histone variants as safe, viable drug targets represents a beacon of hope in the complex and nuanced landscape of cancer biology. It heralds a future where chromatin-targeted therapies can join the therapeutic armamentarium, providing new strategies against relapse and resistance that have long beleaguered clinicians and patients alike. This research exemplifies how deep mechanistic exploration coupled with rigorous in vivo validation can transform once theoretical targets into tangible pathways toward cures.

Subject of Research: Animals

Article Title: Loss of histone macroH2A1.1 causes kidney abnormalities secondary to a change in nutrient metabolization

News Publication Date: 24-Oct-2025

Web References:
http://dx.doi.org/10.1126/sciadv.adz1242

References:
René Winkler et al. “Loss of histone macroH2A1.1 causes kidney abnormalities secondary to a change in nutrient metabolization”. Sci. Adv., Vol 11, Issue 43.

Image Credits:
Josep Carreras Leukaemia Research Institute

Keywords:
Histones, Chromatin, Myeloid leukemia, Cancer, Leukemia

Dr. Melnick brings to the institute an exceptional breadth of expertise in hematological research. With a medical degree from the University of Buenos Aires earned in 1990, he has cultivated an illustrious career at top-tier institutions such as the Mount Sinai School of Medicine and the Weill Cornell Cancer Center in New York. His role as the leader of the Hematologic Malignancies Program at Weill Cornell and his distinguished appointment as the Gebroe Family Professor since 2013 speak to his profound impact on hematologic oncology. Dr. Melnick’s pioneering work on epigenetics in blood cancers has redefined our understanding of tumor biology and therapeutic resistance.

Central to Dr. Melnick’s research is the exploration of epigenetic dysregulation as a hallmark of cancer. His investigations demonstrated that aberrant epigenetic programming — modifications to DNA and chromatin that control gene expression without altering the underlying genome — substantially influences the malignant phenotype and clinical outcomes. His lab was among the earliest to develop rational transcription factor inhibitors, designed to disrupt the aberrant gene regulatory networks that sustain tumor growth and survival. These inhibitors represent a revolutionary class of targeted therapies, addressing one of the most challenging aspects of cancer biology: the “undruggable” nature of transcription factors.

Dr. Melnick’s contribution to cancer epigenetics extends to comprehensive epigenomic mapping across diverse patient populations. By leveraging next-generation sequencing and advanced bioinformatics, his team elucidated the landscape of epigenetic heterogeneity within tumors, revealing that increased epigenetic diversity correlates with tumor fitness, therapeutic resistance, and adverse clinical prognoses. This paradigm shift underscores the necessity of integrating epigenetic biomarkers into diagnostic and therapeutic frameworks to achieve precision oncology.

The translational aspect of Dr. Melnick’s work is underscored by the fact that several therapeutic candidates originating from his research have either received FDA approval or progressed to late-stage clinical trials. This success has garnered him prestigious recognition, including the American Society of Hematology Ernest Beutler Prize in Translational Research, highlighting the clinical relevance of his scientific discoveries. Furthermore, his influence extends beyond the laboratory through his service on the Board of Directors for the Leukemia and Lymphoma Society and the Lymphoma Research Foundation, where he helps shape the strategic direction of the field.

Speaking on his new role, Dr. Melnick emphasized the institute’s remarkable trajectory and global reputation in advancing blood cancer research. He expressed excitement about building on the institute’s momentum to accelerate the development of innovative therapies and improve patient outcomes. As a clinician-scientist, Dr. Melnick appreciates the institute’s unique positioning to translate scientific breakthroughs swiftly from bench to bedside, leveraging its collaborative network of world-class hospitals and research centers in Barcelona.

Dr. Melnick envisions an enhanced translational research ecosystem at the Josef Carreras Institute, where multidisciplinary teams integrate systems biology, artificial intelligence, and high-throughput technologies to unravel the complex molecular mechanisms driving blood cancers. The incorporation of tumor 3D reconstruction models and physiologically relevant disease platforms aims to bridge the gap between in vitro studies and human disease, enabling more predictive preclinical evaluation of novel therapeutics. This approach aligns with the emerging trend of precision medicine, where therapies are tailored based on individual tumor biology.

A key strategic priority under Dr. Melnick’s leadership is expanding the institute’s global collaborations to maximize scientific innovation and patient benefit. By forging alliances with premier research centers across Europe, the Americas, and Asia, the institute plans to create an international consortium that fosters knowledge exchange, harmonizes clinical trial efforts, and accelerates biomarker-driven drug development. This global outlook is critical to tackling the heterogeneity and complexity of hematologic malignancies that transcend geographic boundaries.

The Josep Carreras Foundation’s unwavering dedication has been a vital catalyst in the institute’s achievements. Dr. Melnick expressed profound admiration for the foundation’s commitment to supporting ambitious research programs and fostering a nurturing environment for scientific excellence. This foundation-driven backing provides indispensable resources that enable the institute to attract top-tier talent, innovate rapidly, and maintain a patient-centered mission.

Under Dr. Melnick’s guidance, the institute aims to harness cutting-edge technologies such as artificial intelligence to analyze multi-dimensional datasets generated from genomics, epigenomics, proteomics, and clinical parameters. These integrative computational methodologies promise to identify novel therapeutic targets, predict treatment responses, and guide personalized treatment strategies. The prospect of AI-driven systems biology marks a new frontier in understanding blood cancer pathogenesis and improving clinical care.

Dr. Melnick’s vision also involves strengthening efforts in the development of dynamic disease models that capture tumor microenvironment interactions and drug resistance mechanisms. The application of 3D cell cultures and organoid systems enhances the physiological relevance of preclinical studies, providing a platform to test drug efficacy and toxicity more accurately. This innovation is anticipated to refine therapeutic regimens and reduce attrition rates in clinical development.

The appointment of Dr. Ari Melnick heralds a new chapter for the Josep Carreras Leukaemia Research Institute, reaffirming its status as a leading center for hematologic cancer research worldwide. By combining visionary leadership, scientific rigor, and collaborative spirit, the institute is poised to accelerate breakthroughs that will transform the landscape of blood cancer diagnosis and therapy, ultimately improving survival and quality of life for patients globally.

Image Credits: Dr Ari Melnick

Keywords: Blood cancer, Lymphoma, Leukemia